156,422 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Man Group plc

Posted by Geri Gentry on Aug 30th, 2026

Man Group plc bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 156,422 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,275,000. Man Group plc owned approximately 0.27% of Supernus Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Rockefeller Capital Management L.P. increased its stake in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 458 shares during the period. Global Retirement Partners LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $64,000. Vestcor Inc bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at approximately $67,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at approximately $51,000.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $43.73 on Friday. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The firm’s 50-day moving average is $46.81 and its two-hundred day moving average is $48.66. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of -22.78, a PEG ratio of 0.81 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. During the same quarter in the prior year, the firm posted $0.40 EPS. The company’s revenue for the quarter was up 32.4% compared to the same quarter last year. On average, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

Get Our Latest Research Report on Supernus Pharmaceuticals

Supernus Pharmaceuticals Profile

(Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.